Filtros de búsqueda

Lista de obras de Francis J Giles

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

scientific article published on 22 January 2020

A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma

artículo científico publicado en 2021

A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia

artículo científico publicado en 2004

A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia

artículo científico publicado en 2008

Accelerated and blastic phases of chronic myelogenous leukemia

artículo científico publicado en 2004

Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells

artículo científico publicado en 2006

Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes

artículo científico publicado en 2005

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia

artículo científico publicado en 2003

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center

artículo científico publicado en 2005

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

artículo científico publicado en 2003

Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay.

artículo científico publicado en 2004

Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia

artículo científico publicado en 2003

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders

artículo científico publicado en 2003

Anaplastic lymphoma kinase mutation (ALK F1174C) in small cell carcinoma of the prostate and molecular response to alectinib.

artículo científico publicado en 2018

Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial

scientific article published on 06 May 2019

Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival

artículo científico publicado en 2002

CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia

artículo científico publicado en 2002

Central nervous system relapse in adults with acute lymphoblastic leukemia

artículo científico publicado en 2002

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

artículo científico publicado en 2006

Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease

scientific article published on 01 December 2003

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis

artículo científico publicado en 2017

Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation

artículo científico publicado en 2006

Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma

artículo científico publicado en 2004

Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease

scientific article published on 20 March 2006

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

artículo científico publicado en 2006

Combined targeting of the BRD4-NUT-p300 axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734

scientific article published on 05 May 2020

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

artículo científico publicado en 2003

Current and emerging treatment options in chronic myeloid leukemia

artículo científico publicado en 2007

DNA methylation in haematological malignancies: the role of decitabine

artículo científico publicado en 2003

Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.

artículo científico publicado en 2009

Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.

artículo científico publicado en 2007

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation

artículo científico publicado en 2006

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit

artículo científico publicado en 2006

Eradication of minimal residual disease in hairy cell leukemia

artículo científico publicado en 2006

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

artículo científico publicado en 2003

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

artículo científico publicado en 2002

Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia

artículo científico publicado en 2004

Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit

artículo científico publicado en 2003

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi

artículo científico publicado en 2002

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

artículo científico publicado en 2003

Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response

scientific article published on 18 September 2019

High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses

artículo científico publicado en 2009

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

artículo científico publicado en 2002

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

artículo científico publicado en 2002

Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.

artículo científico publicado en 2002

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data

artículo científico publicado en 2003

Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors

artículo científico publicado en 2007

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

artículo científico publicado en 2017

In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines

artículo científico publicado en 2003

Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome

artículo científico publicado en 2003

Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia

artículo científico publicado en 2003

Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986

artículo científico publicado en 2005

Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors

artículo científico publicado en 2008

Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.

artículo científico publicado en 2007

Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

artículo científico publicado en 2011

Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia

artículo científico publicado en 2003

Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia

artículo científico publicado en 2002

Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia

artículo científico publicado en 2003

New approaches in the treatment of myelofibrosis

artículo científico publicado en 2005

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis

artículo científico publicado en 2017

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

artículo científico publicado en 2010

Novel approaches in the treatment of systemic mastocytosis

artículo científico publicado en 2006

Novel therapies for patients with chronic myeloid leukemia

artículo científico publicado en 2004

Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity

scientific article published on 01 July 2007

Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies

artículo científico publicado en 2006

Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma

artículo científico publicado en 2004

PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study

artículo científico publicado en 2007

Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies

artículo científico publicado en 2005

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

artículo científico publicado en 2003

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

artículo científico publicado en 2010

Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

artículo científico publicado en 2003

Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia

artículo científico publicado en 2002

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia

artículo científico publicado en 2004

Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome

artículo científico publicado en 2008

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

artículo científico publicado en 2004

Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma

artículo científico publicado en 2004

Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases

artículo científico publicado en 2003

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

artículo científico publicado en 2003

Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders

artículo científico publicado en 2002

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia

artículo científico publicado en 2002

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

artículo científico publicado en 2003

Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy

artículo científico publicado en 2007

Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia

artículo científico publicado en 2002

Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia

artículo científico publicado en 2003

Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia

artículo científico publicado en 2002

Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia.

artículo científico publicado en 2006

Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia

artículo científico publicado en 2006

Proteomics-based prediction of clinical response in acute myeloid leukemia

artículo científico publicado en 2009

Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.

artículo científico publicado en 2003

Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.

artículo científico publicado en 2003

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

artículo científico publicado en 2004

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

artículo científico publicado en 2003

Rituximab in relapsed or refractory hairy cell leukemia

artículo científico publicado en 2003

Role of artificial intelligence in the care of patients with nonsmall cell lung cancer

artículo científico publicado en 2018

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

artículo científico publicado en 2003

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia

artículo científico publicado en 2002

Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia

artículo científico publicado en 2003

T-cell prolymphocytic leukemia: a single-institution experience

scientific article published on 01 November 2005

Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma

scientific article published on 17 May 2019

Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia

artículo científico publicado en 2005

Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia

artículo científico publicado en 2004

Thalidomide therapy for myelofibrosis with myeloid metaplasia

scientific article published on 01 May 2006

The role of gemtuzumab ozogamicin in acute leukaemia therapy

artículo científico publicado en 2006

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

artículo científico publicado en 2003

Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside

artículo científico publicado en 2003

Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.

artículo científico publicado en 2002

Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome

artículo científico publicado en 2006

Troxacitabine activity in extramedullary myeloid leukemia

artículo científico publicado en 2002

Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation

artículo científico publicado en 2004

Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse

scientific article published on 01 July 2006

WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation

artículo científico publicado en 2008

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda